NewsRoom

Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013

20122011201020092008

May 15, 2019
MEI Pharma to Present New Clinical Results on ME-401 and ME-344 Programs at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
International Conference on Malignant Lymphoma (ICML) Selects ME-401 Abstract for Oral Presentation
May 9, 2019
MEI Pharma Reports Third Quarter Fiscal Year 2019 Results and Operational Highlights
Apr 2, 2019
MEI Pharma to Present at the 18th Annual Needham Healthcare Conference
Mar 12, 2019
MEI Pharma to Present at the 29th Annual Oppenheimer Healthcare Conference
Feb 14, 2019
Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in the Frontline Treatment of Older AML Patients Unfit for Intensive Chemotherapy, in Blood Advance
Feb 7, 2019
MEI Pharma Reports Second Quarter Fiscal Year 2019 Results and Operational Highlights
-- MEI Remains in Strong Position as ME-401 Advances to Global Phase 2 Study to Support FDA Accelerated Approval --
Dec 3, 2018
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting
Dec 2, 2018
MEI Pharma Presents Clinical Data from Ongoing Phase 1b Study of ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Hematology Annual Meeting
- Data Support Complementary Potential of Intermittent and Continuous Dosing Schedules as Means to Optimize Clinical Risk-Benefit Ratio in Relapsed/Refractory Follicular Lymphoma Patients -
Dec 1, 2018
MEI Pharma Presents Preclinical Data Demonstrating Voruciclib Synergistically Induces Apoptosis in Combination with Venetoclax in Acute Myeloid Leukemia Cells at the 2018 American Society of Hematology Annual Meeting
Nov 8, 2018
MEI Pharma Reports First Quarter Fiscal Year 2019 Results and Operational Highlights
-- MEI on Track to Initiate ME-401 Phase 2 Accelerated Approval Study Around Year-End --
Nov 6, 2018
MEI Pharma To Present at Stifel 2018 Healthcare Conference
Nov 5, 2018
MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan
MEI to Receive $10 Million Upfront Payment, Plus Milestones and Tiered Royalty Payments
Nov 1, 2018
MEI Pharma to Present Clinical Data from Three Oncology Programs at the 2018 American Society of Hematology (ASH) Annual Meeting
Oct 11, 2018
MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies
Aug 30, 2018
MEI Pharma Reports Fiscal Year 2018 Results and Operational Highlights
-Fiscal Year 2018 Highlighted by Progress Across All Four Clinical-stage Oncology Candidates; ME-401 Accelerated Approval Study to Start by Year-end 2018-